Clinical assets
Thank you for your interest in learning more about the testing solutions we offer. Feel free to browse the brochures below.
Clicking on the brochure will open it, allowing you to download.
PanTracer™ Pro
Simplifies case management and enables a path to personalized treatment, providing comprehensive insights in a single order.
PanTracer™ Tissue
Broad tissue-based CGP covering 517 genes with DNA + RNA sequencing for optimized fusion detection. Aligns with clinical guidelines and requires minimal tissue, enabling personalized therapy selection and trial matching.
RaDaR® ST
RaDaR® ST for breast cancer
Address HR+/HER2- breast cancer long-term recurrence risk months before conventional methods. RaDaR ST provides over a year's advance warning of distant metastasis, opening the door to life-changing interventions.
RaDaR® ST for head & neck cancer
RaDaR ST delivers unprecedented sensitivity in detecting HPV-negative HNSCC recurrence, achieving 100% detection of relapsed patients by identifying ctDNA at ultra-low levels of 5ppm—ensuring no patient with recurrent disease goes undetected during the critical surveillance window.
Hematology solutions
Compass®
Compass Hematopathology Services is a streamlined and personalized lab workup to help inform effective patient care management by providing diagnostic clarity to complex hematologic malignancies and prognostic and predictive information.
Neo Comprehensive® - Heme Cancers
The Neo Comprehensive – Heme Cancers assay analyzes 433 genes using next‑generation sequencing (NGS) to detect DNA and RNA alterations for diagnostic evaluation, prognosis, risk stratification, and therapy guidance in hematologic malignancies.
